Anixa Biosciences Inc
For the period ended Jan 31, 2024. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jan 31, 2024 · Filed Mar 12, 2024
ANIX$3.18+4.8%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets (Unaudited) as of January 31, 2024 and October 31, 2023
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands, except share and per share data)
| January 31, 2024 | October 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $998 | $915 |
| Short-term investments | 22,800 | 22,929 |
| Receivables | 391 | 270 |
| Prepaid expenses and other current assets | 1,030 | 1,242 |
| Total current assets | 25,219 | 25,356 |
| Operating lease right-of-use asset | 153 | 166 |
| Total assets | $25,372 | $25,522 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $364 | $206 |
| Accrued expenses | 1,242 | 1,770 |
| Operating lease liability | 54 | 52 |
| Total current liabilities | 1,660 | 2,028 |
| Operating lease liability, non-current | 108 | 123 |
| Total liabilities | 1,768 | 2,151 |
| Commitments and contingencies (Note 10) | - | - |
| Equity: | ||
| Shareholders’ equity: | ||
| Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding | - | - |
| Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding | - | - |
| Common stock, par value $.01 per share; 100,000,000 shares authorized; 31,754,375 and 31,145,219 shares issued and outstanding as of January 31, 2024 and October 31, 2023, respectively | 318 | 311 |
| Additional paid-in capital | 255,738 | 252,222 |
| Accumulated deficit | (231,451) | (228,196) |
| Total shareholders’ equity | 24,605 | 24,337 |
| Noncontrolling interest (Note 2) | (1,001) | (966) |
| Total equity | 23,604 | 23,371 |
| Total liabilities and equity | $25,372 | $25,522 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.